Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVNS
AVNS logo

AVNS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Avanos Medical Inc (AVNS) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

No data

No data

Growth

Profitability

Efficiency

Wall Street analysts forecast AVNS stock price to rise
Analyst Rating
0
Wall Street analysts forecast AVNS stock price to rise
Buy
Hold
Sell
0
Current: 24.620
sliders
Low
0
Averages
0
High
0
0
Current: 24.620
sliders
Low
0
Averages
0
High
0
Barclays
NULL -> Overweight
upgrade
$9 -> $11
AI Analysis
2026-01-16
Reason
Barclays
Price Target
$9 -> $11
AI Analysis
2026-01-16
upgrade
NULL -> Overweight
Reason
Barclays raised the firm's price target on Aveanna to $11 from $9 and keeps an Overweight rating on the shares. The firm upped estimates post the company's Q4 preannouncement.
William Blair
Jared Haase
Outperform
initiated
2025-12-08
Reason
William Blair
Jared Haase
Price Target
2025-12-08
initiated
Outperform
Reason
William Blair analyst Jared Haase initiated coverage of Aveanna with an Outperform rating. Preferred payers are producing a more respectable growth algorithm, the analyst tells investors in a research note. Aveanna is positioned as an attractive smid-cap healthcare services holding, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AVNS
Unlock Now

People Also Watch